Search

everythinglearnresearchcommunity

for

Search:↓

A new hair loss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.

A 23-year-old male shared his 6-month hair transformation using Dutasteride, oral Minoxidil, ketoconazole shampoo, vitamin D, gym, cardio, and dermastamping. He reported significant hair maintenance and no side effects.

User tried DIY Dutasteride Mesotherapy for hair loss due to unsatisfactory Finasteride results. Used mesotherapy injection gun and liquid dutasteride for better results and fewer side effects.

The conversation is about the double standard in the hair loss community regarding shedding when using different treatments. The conclusion is that shedding is considered normal when starting finasteride or minoxidil, but not when starting dutasteride, despite the fact that dutasteride is more effective at reducing DHT.

Hair loss treatments Finasteride and Dutasteride are discussed, with emphasis on their safety and effectiveness. Users share frustration about fear-mongering and side effect discussions, suggesting trust in scientific studies and FDA approval.

The conclusion of this conversation is that the user "DuckSeasonCamelSeasn" found that consuming grapefruit juice prior to taking finasteride or dutasteride helped them become a responder to the medications and regain hair growth. However, there are warnings about potential risks and interactions with other medications, so caution should be exercised.

A user shared 14-month progress pictures using topical finasteride and minoxidil for hair loss. Others commented on the impressive results and asked about age, improvement timeline, and how to obtain finasteride.

The conversation suggests that people should consult a dermatologist to understand their type of hair loss before starting treatments like finasteride or dutasteride, especially if they have autoimmune issues or low DHT. Some participants believe in starting treatment like finasteride immediately if hair loss is due to DHT, while others recommend ruling out other causes and considering minoxidil first, especially for younger individuals.

The conversation is about the effectiveness of 0.25% topical finasteride compared to other concentrations and forms. Users discuss its potential for better scalp DHT reduction and fewer side effects, with some preferring topical over oral treatments.

A 20-year-old is using minoxidil for hair regrowth and considering finasteride despite concerns about side effects. Many suggest adding finasteride to maintain gains, with recommendations to start with a low dose or use a topical form to minimize side effects.

A user shared their 5-month hair regrowth progress using 5% topical minoxidil daily, microneedling weekly, and ketoconazole shampoo twice a week. Some suggest adding finasteride to maintain results, while others commend the current regimen's effectiveness.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

A 37-year-old male stopped using finasteride and minoxidil due to side effects and switched to derma rolling, scalp massaging, and Revita shampoo, resulting in thicker, healthier hair with new growth. Users discuss the effectiveness of mechanical scalp stimulation, with some sharing similar positive experiences and others expressing skepticism.

A new drug can regrow teeth, but hair loss treatments like Minoxidil, finasteride, and RU58841 are still being developed. Users express hope for future advancements and discuss the importance of mental health and the potential profitability of hair loss solutions.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Some people find topical minoxidil effective for hair loss, but oral minoxidil doesn't work for them, possibly due to absorption issues. Others have had better results with oral minoxidil, suggesting individual responses vary.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The post is about a user's progress with using finasteride, minoxidil, and dermarolling for hair loss. The conversation includes comments about different treatments and methods used.

A 19-year-old experienced worsening hair loss after 4 months on finasteride, despite initial improvement with minoxidil. The consensus is to continue treatment for at least a year, as shedding is common and often temporary.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.

Comparing the effectiveness of minoxidil 5% and adenosine 0.75% for treating male androgenetic alopecia, and measuring patient satisfaction rate; results showed that adenosine is comparable to minoxidil but provides quicker results, however availability of products with adenosine is much less than those with minoxidil.

The struggles of hair loss at a young age and available treatments, such as medication (Finasteride, Minoxidil, Dutasteride, Derma Rolling) and potential options for hair systems or cloning in Japan. People discussed their own experiences with trying to cope with the emotional aspects of this condition.

This user has had success with Minoxidil foam, achieving significant hair growth in three months without using finasteride or derma rolling. They are considering incorporating a DHT reducing strategy such as finasteride in the future.